Edarbi (azilsartan medoxomil tablets; Takeda Pharmaceuticals North America) has been approved by the FDA for the treatment of hypertension in adults. This approval was based on data from Phase 3 clinical trials which showed that Edarbi successfully met the primary endpoint, change in 24-hour mean systolic blood pressure (SBP), with statistical significance of lowering blood pressure compared to placebo and head-to-head active comparators. Results from one study showed Edarbi at doses of 80 mg/day and 40 mg/day lowered 24-hour mean SBP by 14.3mmHg and 13.2mmHg from baseline, respectively. The blood pressure reductions of Edarbi (80 mg/day) were statistically superior to those of the active comparators valsartan 320mg/day (-10mmHg) and olmesartan medoxomil 40mg/day (-11.7mmHg). Similar results were observed in all three comparator studies.   

Edarbi will be available in 40mg and 80mg dosage strengths.

For more information call (877) 825-3327 or visit www.tpna.com.